Immunic Inc (NAS:IMUX)

$ 1.2 0.06 (5.26%) Market Cap: 108.09 Mil Enterprise Value: 49.92 Mil PE Ratio: 0 PB Ratio: 2.62 GF Score: 43/100

Q3 2024 Immunic Inc Earnings Call Transcript
Nov 07, 2024

$1.18

Earnings
Q2 2024 Immunic Inc Earnings Call Transcript
Aug 08, 2024

$1.34 (+14.53%)

Earnings
Q3 2023 Immunic Inc Earnings Call Transcript
Nov 14, 2023

$0.9902 (+2.16%)

Earnings
Immunic Inc To Discuss Interim Data Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS Call Transcript
Oct 10, 2023
Q2 2023 Immunic Inc Earnings Call Transcript
Aug 03, 2023

$2.13 (-1.39%)

Earnings
Immunic Inc To Host Key Opinion Leaders Transcript
Jul 20, 2023
Q1 2023 Immunic Inc Earnings Call Transcript
May 11, 2023

$1.82 (+1.68%)

Earnings
Immunic Inc To Discuss IMU-856 Clinical Phase 1b Results in Celiac Disease Call Transcript
May 04, 2023
Immunic Inc To Discuss Phase 2b CALDOSE-1 Maintenance Phase Data Call Transcript
Apr 05, 2023
Q4 2022 Immunic Inc Earnings Call Transcript
Feb 23, 2023

$1.97 (+4.23%)

Earnings
Immunic Inc Celiac Disease R&D Webcast Transcript
Feb 09, 2023
Immunic Inc Corporate Call Transcript
Nov 17, 2022
Q3 2022 Immunic Inc Earnings Call Transcript
Nov 03, 2022

$1.58 (-7.60%)

Earnings
Immunic Inc Webinar: IMU-856 Phase 1 SAD/MAD Data in Healthy Human Subjects Transcript
Sep 20, 2022
Q2 2022 Immunic Inc Earnings Call Transcript
Aug 04, 2022

$4.79 (+23.14%)

Earnings
Immunic Inc Corporate Update Transcript
Jun 02, 2022
Q1 2022 Immunic Inc Earnings Call Transcript
May 10, 2022

$5.5 (+5.36%)

Earnings
Q4 2021 Immunic Inc Earnings Call Transcript
Feb 24, 2022

$10.72 (-9.15%)

Earnings
Q3 2021 Immunic Inc Earnings Call Transcript
Nov 04, 2021

$10.25 (+2.60%)

Earnings
Immunic Inc Discuss Overall MS Development Strategy - Corporate Call Transcript
Jul 01, 2021
Q2 2020 Immunic Inc Earnings Call Transcript
Aug 03, 2020

Earnings

Immunic Inc To Discuss Interim Data Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS Call Transcript

Oct 10, 2023 / 12:00PM GMT

Release Date Price: $1.37 (-13.84%)

Transcript

Jessica Breu

Immunic, Inc. - Head of IR & Communications

Good morning to our audience today. I would like to welcome you to Immunic's webcast to present the positive interim data from our Phase II CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis, reported after the market closed yesterday.

My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's webcast. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; and Dr. Andreas Muehler, our Chief Medical Officer. (Operator Instructions) And this event is being recorded. After today's presentation, there will be an opportunity to ask questions. (Operator Instructions).

Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.